K

Kaiser Permanente Los Angeles Medical Center | Department of Research and Evaluation

Research site
(Unclaimed)
Location
4733 W. Sunset Boulevard 2nd Floor Suite 230, Los Angeles, California, United States of America

Site insights

Top conditions

Top treatments

Carboplatin
Paclitaxel
Bevacizumab
Cisplatin
Nivolumab
Gemcitabine Hydrochloride
Temozolomide
Atezolizumab
Docetaxel
Pembrolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

27 of 247 total trials
Status recently updated

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) (ROCKET-Ignite)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Enrolling
Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) st...

Enrolling
Hypertension
Familial Primary Pulmonary Hypertension
Drug: Ralinepag
Drug: Placebo

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Ph...

Invitation-only
Hypertension
Familial Primary Pulmonary Hypertension
Drug: Ralinepag

Approximately 216 patients with acute pancreatitis and accompanying SIRS will be randomized at approximately 30 sites. Patients will be randomly assi...

Active, not recruiting
Systemic Inflammatory Response Syndrome
Acute Pancreatitis
Drug: CM-4620 Injectable Emulsion or CM-4620-IE
Other: Placebo

IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (d...

Enrolling
Pulmonary Arterial Hypertension
Drug: Placebo
Drug: AV-101

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valv...

Enrolling
Atrial Fibrillation
Stroke
Drug: Non-Vitamin K Oral Antagonists
Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)

The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Set...

Enrolling
Stroke
Patent Foramen Ovale
Device: AMPLATZER™ PFO Occluder

The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN®...

Active, not recruiting
Stroke
Device: WATCHMAN Left Atrial Appendage Closure
Device: Amulet Left Atrial Appendage Occluder

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Lead...

Active, not recruiting
Bradycardia
Cardiac Rhythm Disorder
Device: Aveir DR Leadless Pacemaker System

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor D...

Enrolling
Stage III Colon Cancer
Drug: mFOLFOX6 3-6 month
Device: Signatera test

The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lo...

Enrolling
Stroke
Intracranial Arteriosclerosis
Other: Risk Factor Management
Drug: Rivaroxaban + Aspirin

This study will test any good and bad effects of the study drug called enzalutamide. Enzalutamide could shrink the cancer but it could also cause sid...

Active, not recruiting
Salivary Cancer
Drug: enzalutamide

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patie...

Active, not recruiting
Hormone-resistant Prostate Cancer
Stage IV Prostate Cancer
Drug: prednisone
Drug: enzalutamide

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant...

Enrolling
Glioma
H3 K27M
Other: Placebo
Drug: ONC201

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemo...

Active, not recruiting
Ovarian Neoplasms
Fallopian Tube Adenocarcinoma
Drug: Paclitaxel
Drug: Carboplatin

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment o...

Enrolling
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Biological: Pembrolizumab
Biological: Ramucirumab

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute...

Enrolling
Intracerebral Hemorrhage
Biological: Recombinant Activated Factor VII (rFVIIa)
Biological: Placebo

Trial sponsors

National Cancer Institute (NCI) logo
S
N
Alliance for Clinical Trials in Oncology logo
Abbott logo
G
G
C
Kaiser Permanente logo
ECOG-ACRIN Cancer Research Group logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems